Northwell Health, one of New York State’s largest health care providers has announced a partnership with Peerbridge Health Inc., a Health IT and wearable technology company to help bring the future of remote heart monitors to life. Founded in 2012, Peerbridge’s cloud-based algorithms connect patients and consumers through multiple on-body wireless sensors conveying powerful intelligence effortlessly with wellness professionals to enable a more timely and proactive care.
The strategic partnership further solidifies Northwell’s commitment to improving the patient experience and the health of the communities it serves throughout the New York metropolitan area, and reducing operational cost.
The American Heart Association reports cardiovascular disease and stroke as the top two killers of American adults and cardiovascular monitoring, both inside and outside medical environments, is critical for diagnosis, proper treatment, and improved outcomes.
o better understand the potential of this partnership, Peerbridge Health and Northwell conducted a clinical trial to measure the performance of the company’s flagship product, the Peerbridge Cor™, a compact, lightweight, multi-channel electrocardiogram monitor. To ensure efficacy, the Peerbridge Cor was compared to other cardiovascular monitors in a clinical trial.
During an ambulatory electrocardiogram (ECG) clinical trial at Lenox Hill Hospital, Peerbridge Cor technology was evaluated side-by-side to the traditional gold standard ECG technology (Holter). The trial demonstrated that the Cor was superior to the current Holter Monitor standard and delivered excellent, multi-channel, analyzable data with less motion artifact and fewer false positives.
“The trial demonstrated this technology was superior to the current Holter Monitor standard,” said Nicholas Skipitaris, MD, chief of electrophysiology at Lenox Hill Hospital. “Not only did the Peerbridge Cor deliver excellent, multi-channel, analyzable data, but it delivered less motion artifact and fewer false positives, despite our patient’s active New York lifestyle.”
The Cor is currently under FDA review with clearance anticipated in 2017.